LOS ANGELES -- (BUSINESS WIRE) -- The Gores Group, a global investment firm focused on acquiring controlling interests in mature and growing businesses, today announced that it has completed the acquisition of Therakos, Inc. from Ortho-Clinical Diagnostics, Inc. Terms of the transaction were not disclosed.
Therakos, based in Raritan, New Jersey, is a global leader in advanced technologies for extracorporeal photopheresis. THERAKOS® Photopheresis Systems are the only integrated systems for extracorporeal photopheresis, a leukapheresis-based immunomodulatory therapy that has been approved by the U.S. Food and Drug Administration for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma unresponsive to other forms of treatment. The unique system has a demonstrated track record of efficacy and safety and has been used globally for more than 25 years.
Michael Rechtiene, the newly appointed CEO of Therakos, stated, “Therakos has been a pioneer in bringing generations of photopheresis therapy to patients around the world. The new generation THERAKOS™ CELLEX® Photopheresis System incorporates innovative and advanced technologies, providing a new level of care that can also significantly reduce treatment times.”
“Therakos’ leadership position and history of innovation puts Therakos in a great position to continue to meet and exceed the expectations of our customers as an independent company,” stated Edward Johnson, Managing Director of The Gores Group. “Therakos is another vital step in Gores’ expansion into the healthcare industry and we are excited for this opportunity.”
About The Gores Group
The Gores Group, LLC is a global investment firm focused on acquiring controlling interests in mature and growing businesses which can benefit from the firm's operating experience and flexible capital base. The firm combines the operational expertise and detailed due diligence capabilities of a strategic buyer with the seasoned M&A team of a traditional financial buyer. The Gores Group, which was founded in 1987 by Alec E. Gores, has become a leading investor having demonstrated over time a reliable track record of creating substantial value in its portfolio companies alongside management. Headquartered in Los Angeles, The Gores Group maintains offices in Boulder, CO, and London. For more information, please visit www.gores.com.
Important Safety Information
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems.
Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
View complete Prescribing Information and Important Safety Information available at http://www.therakos.com/healthcare-professionals/photopheresis/clinical-evidence/safety